세계의 블루 바이오테크놀러지 시장 : 제품별, 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Blue Biotechnology Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

The Blue Biotechnology Market is expected to increase from USD 5.65 billion in 2024 to USD 10.54 billion by 2032, with a compound annual growth rate (CAGR) of 7.15% over the forecast period (2024-2032). The global market is being driven by increased awareness of blue biotechnology-based nutraceuticals and pharmaceuticals, as well as strategic initiatives involving medicines and nutraceuticals derived from marine creatures.

The growing awareness of blue biotechnology-based nutraceuticals and medicines is a key factor driving the blue biotechnology industry forward. As consumers become more aware of the health benefits of marine-derived substances, there is an increasing demand for items derived from marine species. Nutraceuticals containing marine components, such as omega-3 fatty acids, antioxidants, and minerals, are becoming increasingly popular due to their supposed health benefits.

Furthermore, a surge in strategic activities aiming at pharmaceutical and nutraceutical goods generated from marine organisms is propelling the Blue Biotechnology Market. As the pharmaceutical and nutraceutical companies seek new ways to address increasing healthcare and dietary demands, their attention has switched to the ocean's immense and largely unexplored resources.

Market Segment insights

The Blue Biotechnology Market is divided into several product categories, including enzymes, pharmaceuticals, bulk chemicals, biopolymers, and others.

The Blue Biotechnology Market is divided into several types, including bioengineering, genomics, vaccine development, drug research, fisheries, aquaculture, biofuels, water treatment services, and others.

The blue biotechnology market is divided into four end user segments: hospitals, pharmaceutical firms, biotechnology businesses, and others.

Regional insights

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America had the biggest market share of approximately 36.04% in 2023, owing to increased investment in R&D activities, improved healthcare infrastructure, and the presence of established medication manufacturers in the region. Furthermore, the presence of well-known industry players who are actively involved in meeting consumer demand in the region is boosting the market's growth.

The European blue biotechnology market is expected to increase significantly during the forecast year, 2024-2032, due to the existence of numerous blue biotechnology start-ups. For example, the Calouste Gulbenkian and Oceano Azul Foundations, both based in Portugal, have received more than 120 blue biotechnology-related proposals from over 30 countries through September 2020.

The Asia-Pacific blue biotechnology market is expected to develop the quickest over the forecast period, driven by rising demand for marine-derived goods in industries such as agriculture, medicines, and cosmetics. Furthermore, improvements in biotechnological tools and techniques such as genomics, proteomics, and metabolomics have made it easier to research and use marine resources, resulting in increased market growth. These methods enable researchers to more efficiently detect, isolate, and extract important chemicals from marine species.

Major Players

Marinomed Biotech AG (Austria), Marshall Marine Products (India), Marinova (Australia), Aker BioMarine (Norway), Pharma Mar (Spain), Cyanotech Corporation (US), ADM (US), Geomarine (India), CP Kelco U.S., Inc. (US), and TerSera Therapeutics LLC (US) are among the key players in the Blue Biotechnology Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING AWARENESS OF BLUE BIOTECHNOLOGY-BASED NUTRACEUTICALS AND PHARMACEUTICALS
  • 4.2.2 RISING STRATEGIC INITIATIVES ASSOCIATED WITH PHARMACEUTICALS AND NUTRACEUTICALS SOURCED FROM MARINE ORGANISMS
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY POLICIES
• 4.4 OPPORTUNITIES
  • 4.4.1 INCREASING INVESTMENT IN THE DEVELOPMENT OF BIOTECHNOLOGY-BASED MEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE INDIA CELL CULTURE MEDIA MARKET
  • 5.2.1 IMPACT ON SUPPLY CHAIN

6 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 ENZYMES
• 6.3 PHARMA PRODUCTS
• 6.4 BULK CHEMICALS
• 6.5 BIOPOLYMERS
• 6.6 OTHERS

7 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 BIOENGINEERING
• 7.3 GENOMICS
• 7.4 VACCINE DEVELOPMENT
• 7.5 DRUG DISCOVERY
• 7.6 FISHERIES
• 7.7 AQUACULTURE
• 7.8 BIOFUELS
• 7.9 WATER TREATMENT SERVICES
• 7.10 OTHERS

8 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS
• 8.3 PHARMACEUTICAL COMPANIES
• 8.4 BIOTECHNOLOGY COMPANIES
• 8.5 OTHERS

9 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 NORWAY
  • 9.3.7 NETHERLANDS
  • 9.3.8 SWITZERLAND
  • 9.3.9 FINLAND
  • 9.3.10 BELGIUM
  • 9.3.11 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 LATIN AMERICA
  • 9.5.2 MIDDLE EAST
  • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE BLUE BIOTECHNOLOGY MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE BLUE BIOTECHNOLOGY MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
  • 10.6.2 AGREEMENT
  • 10.6.3 PARTNERSHIP
  • 10.6.4 ACQUISITION
• 10.7 MAJOR PLAYERS FINANCIAL
  • 10.7.1 SALES (USD MILLION),
  • 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

11 COMPANY PROFILES

• 11.1 MARINOMED BIOTECH AG
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 KEY STRATEGIES
• 11.2 MARSHALL MARINE PRODUCTS/
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 KEY STRATEGIES
• 11.3 MARINOVA
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 AKER BIOMARINE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 PHARMAMAR
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 CYANOTECH CORPORATION
  • 11.6.1 COMPANY OVERVIEWS
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 ADM
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL ANALYSIS
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 GEOMARINE BIOTECHNOLOGIES
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 CP KELCO U.S., INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCT OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 TERSERA THERAPEUTICS LLC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS